Showing results (171-180 of 223) with videos related to

Sort By:
Pageof 23
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 10, 2022
Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and IIJutta Gärtner, Stephen L Hauser, Amit Bar-Or, et al.
Multiple Sclerosis and Related Disorders|April 23, 2021
Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development programKrzysztof W Selmaj, Jeffrey A Cohen, Giancarlo Comi, et al.
Multiple Sclerosis and Related Disorders|October 2, 2023
Magnetic resonance fingerprinting in multiple sclerosisDaniel Ontaneda, Vikas Gulani, Anagha Deshmane, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 30, 2022
Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension studyCorey C Ford, Jeffrey A Cohen, Andrew D Goodman, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 6, 2018
Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension studySibyl Wray, Eva Havrdova, David R Snydman, et al.
Neurology and Therapy|July 24, 2024
Patient Preference for Subcutaneous Versus Intravenous Administration with Every-6-Week Natalizumab (Tysabri®) Dosing: NOVA Phase IIIb Extension Study (Part 2)Heinz Wiendl, John Foley, Gilles Defer, et al.
Contemporary Clinical Trials|April 23, 2020
Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: The DELIVER-MS study protocolDaniel Ontaneda, Emma C Tallantyre, Praneeta C Raza, et al.
The Lancet. Neurology|September 8, 2019
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trialJeffrey A Cohen, Giancarlo Comi, Krzysztof W Selmaj, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 22, 2023
Concurrent administration of serotonergic antidepressants and ozanimod in participants with relapsing multiple sclerosis from the open-label extension DAYBREAK trialRobert T Naismith, Jeffrey A Cohen, Amit Bar-Or, et al.
The Lancet. Neurology|September 8, 2019
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trialGiancarlo Comi, Ludwig Kappos, Krzysztof W Selmaj, et al.
Pageof 23